Abstract
Background Thymidylate synthase (TYMS) constitutes a pivotal and potent target in the context of chemoresistance. However, the oncogenic role of TYMS has received insufficient attention.
Methods Leveraging data from the Cancer Genome Atlas and various public databases, we conducted an extensive investigation into the oncogenic role of TYMS across 33 cancer types.
Results TYMS exhibited pronounced expression across a spectrum of cancers and demonstrated associations with clinical outcomes in diverse cancer patient cohorts. Furthermore, genetic alterations were identified as potential influencers of overall survival in specific tumor types. Notably, the expression of thymidylate synthase correlated with tumor-infiltrating CD4+ cells in select cancers. Additionally, the functional mechanism of TYMS encompassed nucleotidase activity, chromosome segregation, and DNA replication progress.
Conclusions This study furnishes a comprehensive understanding of the oncogenic role played by TYMS in human tumors.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by the Beijing Municipal Natural Science Foundation (No. 7244344), Beijing Chao-yang Hospital Golden Seed foundation (No. CYJZ202201) and the inner-hospital foundation of Beijing Chao-yang Hospital. Besides, we would like to thank Xulei Huo for his technical supports.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors
Abbreviations
- ACC
- Adrenocortical carcinoma
- BLCA
- Bladder Urothelial Carcinoma
- BRCA
- Breast invasive carcinoma Cervical squamous cell carcinoma and endocervical
- CESC
- adenocarcinoma
- CHOL
- Cholangiocarcinoma
- COAD
- Colon adenocarcinoma
- DFS
- Disease free survival
- DLBC
- Diffuse Large B-cell Lymphoma
- dTMP
- deoxythymidine monophosphate
- ESCA
- Esophageal carcinoma
- GBM
- Glioblastoma
- GEPIA2
- Gene Expression Profiling Interactive Analysis, version 2
- GTEx
- Genotype-Tissue Expression
- HNSC
- Head and Neck squamous cell carcinoma
- HPA
- The Human Protein Atlas
- IHC
- Immunohistochemistry
- KICH
- Kidney Chromophobe
- KIRC
- Kidney renal clear cell carcinoma
- KIRP
- Kidney renal papillary cell carcinoma
- LAML
- Acute Myeloid Leukemia
- LGG
- Low grade glioma
- LIHC
- Liver hepatocellular carcinoma
- LUAD
- Lung adenocarcinoma
- LUSC
- Lung squamous cell carcinoma
- MESO
- Mesothelioma
- MHC
- major histocompatibility complex
- NCBI
- National Center for Biotechnology Information
- NK
- Natural killer
- NSCLC
- non-small cell lung carcinoma
- OS
- Overall survival
- OV
- Ovarian serous cystadenocarcinoma
- PAAD
- Pancreatic adenocarcinoma
- PCPG
- Pheochromocytoma and Paraganglioma
- PRAD
- Prostate adenocarcinoma
- READ
- Prostate adenocarcinoma
- SARC
- Sarcoma
- SKCM
- Skin Cutaneous Melanoma
- STAD
- Stomach adenocarcinoma
- TCGA
- The cancer genome atlas
- TGCT
- Testicular Germ Cell Tumors
- THCA
- Testicular Germ Cell Tumors
- THYM
- Thymoma
- TIMER2
- tumor immune estimation resource, version 2
- TPM
- Transcripts per million
- TYMS
- thymidylate synthase
- UCEC
- Uterine Corpus Endometrial Carcinoma
- UCS
- Uterine Carcinosarcoma
- UVM
- Uveal Melanoma